Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

2
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
2
Hybridoma Technology01:31

Hybridoma Technology

18.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.7K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation.

Annals of hematology·2026
Same author

[<sup>18</sup>F]Fluorodeoxyglucose-PET/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Haematologica·2026
Same author

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML.

Cell stem cell·2026
Same author

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Blood·2026
Same author

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome.

Med (New York, N.Y.)·2026
Same author

Haploidentical Allogeneic Cell Transplantation in Relapsed/Refractory Multiple Myeloma.

Cancer management and research·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
查看所有相关文章

相关实验视频

Updated: Apr 19, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

多发性骨髓瘤是一种多发性骨髓瘤.

Christoph Röllig1, Stefan Knop2, Martin Bornhäuser1

  • 1Medizinische Klinik und Poliklinik I, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Lancet (London, England)
|December 27, 2014
PubMed
概括
此摘要是机器生成的。

新型疗法正在改善多发性骨髓瘤患者的治疗结果. 研究重点是平衡治疗效果与生活质量,旨在实现长期缓解和治疗这种血细胞恶性瘤的潜在疗法.

更多相关视频

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

相关实验视频

Last Updated: Apr 19, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学

背景情况:

  • 多发性骨髓瘤是一种骨髓恶性瘤,涉及克隆性血细胞增殖和单克隆性免疫球蛋白分泌.
  • 了解骨髓微环境在疾病进展和治疗耐药性方面的作用,推动了治疗方面的进步.

研究的目的:

  • 审查多发性骨髓瘤治疗的最新进展.
  • 突出新型药物和支持性护理对患者结果的影响.
  • 概述当前的临床研究方向和未来的治疗希望.

主要方法:

  • 对多发性骨髓瘤的当前临床研究和治疗策略的审查.
  • 分析新药 (蛋白酶体抑制剂,免疫调节药物) 在组合治疗中的作用.
  • 考虑自身干细胞移植和支持性护理方面的进展.

主要成果:

  • 新型治疗药物与现有治疗相结合,显著提高了反应率和生存率.
  • 对瘤微环境的理解增加,促进了向治疗的开发.
  • 目前的研究重点是优化治疗顺序,提高生活质量,实现长期缓解.

结论:

  • 多模式治疗策略,包括新药和干细胞移植,已经大大改善了多发性骨髓瘤的预后.
  • 目前正在进行的临床试验和有希望的新疗法管道为持续的进展提供了希望.
  • 未来的研究旨在实现长期缓解和潜在的治愈,同时优先考虑患者的生活质量.